Study Complete
Sponsor ID
20120356
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Study Details
The primary objective of this study was to assess users’ ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
Protocol Summary
Primary Outcome Measures
Combination of subject reported outcomes across two attempted full-dose administrations of evolocumab (AMG 145)
Timeframe: 8 weeks
Secondary Outcome Measures
Percent change from baseline in LDL-C at weeks 10 and 12
Timeframe: 12 weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Marion, OH, United States, 43302
Status
Recruiting
Location
Research Site
Sarnia, ON, Canada, N7T 4X3
Status
Recruiting
Location
Research Site
Cadiz, OH, United States, 43907
Status
Recruiting
Location
Research Site
Ayer, MA, United States, 01432
Status
Recruiting
Location
Research Site
Dallas, TX, United States, 75231
Status
Recruiting
Location
Research Site
Lansdale, PA, United States, 19446
Status
Recruiting
Showing {first} - {last} of {total} Results